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Background: To describe the first reported case of toxic optic neuropathy secondary to docetaxel (Taxotere®)
chemotherapy.
Case presentation: A 53-year-old female presented with predominantly unilateral visual loss, but extensive bilateral
visual field defects and bilateral optic nerve head swelling 2 weeks after first dose of docetaxel (Taxotere®) and
trastuzumab (Herceptin®) chemotherapy for a left sided node-positive, HER2 positive breast cancer. Extensive
investigation ruled out other causes of optic neuropathy. She was treated with high dose corticosteroids
intravenously for 1 week then a tapering oral dose over 8 weeks. Visual field defects gradually resolved and visual
acuity improved. Docetaxel chemotherapy was discontinued but targeted therapy with trastuzumab continued
without further complication.
Conclusion: Docetaxel can cause a toxic optic neuropathy possibly due to an ischemic or neurotoxic mechanism
at the optic nerve head. With cessation of docetaxel therapy and treatment with systemic corticosteroids, visual
recovery can occur without significant residual visual deficit.
Keywords: Toxic optic neuropathy, Toxic, Optic neuropathy, Docetaxel, ChemotherapyBackground
Docetaxel is an anticancer cytotoxic that belongs to the
taxane family. This drug binds to β-tubulin to inhibit the
disassembly of microtubules, thus inhibiting cell replica-
tion and inducing apoptosis [1]. The taxanes are derived
from the bark of the Pacific Yew (Taxus brevfolia) [2]
and are widely accepted as evidence-based components
of therapy for breast, lung, and ovarian carcinomas.
In the adjuvant treatment of breast cancer, these
drugs are most often used in sequence or in combin-
ation with trastuzumab (Herceptin®), doxorubicin and
cyclophosphamide [3].
Systemically, docetaxel most commonly causes myelo-
suppression, neuropathy, myalgias, fatigue, alopecia, diar-
rhoea, mucosal toxicity and skin and nail changes [1].
Rare ophthalmic adverse effects include epiphora [4,5],
canalicular stenosis [6], conjunctivitis [7] and cystic macu-
lopathy [8,9]. Although docetaxel has not previously been* Correspondence: thomas.moloney@health.qld.gov.au
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unless otherwise stated.reported to cause optic neuropathy, paclitaxel has been
implicated in causing transient visual disturbances which
mainly occur during drug infusion and is thought to be
due to vascular dysregulation in retinal and optic nerve
pathways [10,11].
We describe the first reported case of toxic optic neur-
opathy caused by docetaxel chemotherapy and discuss
its significance in the context of previous hypothesized
mechanisms of optic nerve damage caused by taxanes.
Case presentation
A 53-year-old female was admitted to hospital after pre-
senting with a 2-week history of gradually worsening vis-
ual loss in the left eye. She described visual loss which
mainly involved her left inferior visual field. She reported
that her symptoms had started 2 days after infusion of her
first cycle of docetaxel/trastuzumab and had gradually
worsened since that time. She did not report any visual
disturbance at the time of infusion. She reported no other
flashes, floaters, or foreign body sensation. She had no
complaints of pain, headache, red eyes, irritation, lacrima-
tion or photophobia neither jaw claudication, myalgias,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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or any other systemic symptoms.
She was hyperopic but otherwise had no other past
ophthalmic history. She was an active smoker with a 20-
pack year history (currently 10/day) who consumed on
average 30 grams of alcohol per day. She otherwise had
a well-balanced diet and had no known exposures to any
environmental toxins.
She had a past medical history of well-controlled hyper-
tension, gastro-oesphageal reflux disease and hepatic focal
nodular hyperplasia (FNH). She had previously had a hys-
terectomy for fibroids but still had her ovaries in situ.
Her diagnosis of breast cancer occurred 5 months
earlier. Initial treatment involved left breast wide local
excision and sentinel node biopsy, which was followed
by a completion left mastectomy with axillary lymph
node sampling. Histology of the operative specimen was
consistent with a high risk, multi-focal early stage breast
cancer as detailed below:
 Lesion 1- 15 mm × 1.1 mm Grade 3 Invasive
Ductal Carcinoma with extensive lymphovascular
invasion. ER (oestrogen receptor) 90% positive,
PR (progesterone receptor) 20% positive and HER2
positive by SISH (silver in-situ hybridization).
 Lesion 2: 3.5 mm Grade 1 Invasive lobular
carcinoma. ER positive, PR positive, HER2 negative
 There was extensive high-grade ductal carcinoma in
situ (DCIS) of 120 mm on remaining mastectomy
specimen. One out of four axillary lymph nodes was
involved with 3.2 mm macro-metastasis.
Staging CT scan showed a 3.8 cm liver lesion straddling
Segment IVA and Segment VIII, consistent with her
known FNH. There was no evidence of metastatic visceral
disease and a bone scan also ruled bony metastasis.
She was planned to receive adjuvant chemotherapy as
per Slamon et al. called AC-TH involving 4 cycles of 3
weekly doxorubicin and cyclophosphamide (AC); followed
by 4 cycles of 3 weekly concurrent docetaxel and trastuzu-
mab (TH); followed by 3 weekly trastuzumab up to a total
of 52 weeks of treatment [12]. Her body surface area
(BSA) [13] was 1.83 m2 (height: 169 cm, weight: 71.4 kg)
and she had normal baseline renal, hepatic and haemo-
tological function. She was dosed with docetaxel 185 mg
(100 mg/m2 BSA) and Herceptin 572 mg (8 mg/kg
loading dose) [12].
She tolerated her initial 4 cycles of doxorubicin/cyclo-
phosphamide well, but presented with visual disturbance
shortly after her first cycle docetaxel and trastuzumab.
At presentation, her regular medications included ateno-
lol, telmisartan, hydrochlorothiazide, pantoprazole, fish
oil, multivitamin, vitamin D and glucosamine. She was
allergic to codeine.Systemic examination on presentation was normal with
no focal neurology detected. Vital signs were stable with
no hypertension. On ophthalmic examination, her best-
corrected visual acuity was 6/7.5 in the right eye and 6/9
in the left eye. A left relative afferent pupillary defect was
present. Intraocular pressures were 17 in the right eye and
19 in the left eye. Ishihara plate testing showed 15/15 with
a fast response in the right eye and 11/15 with a slow re-
sponse in the left eye. Red saturation testing showed a
40% reduction in the left eye. Extraocular movements
were full and not painful. Temporal arteries were pulsatile
and non-tender and there was no carotid bruit. On slit
lamp examination, anterior segments were quiet apart
from mild nuclear sclerotic cataracts bilaterally. Fundus
examination showed swollen optic nerve heads with asso-
ciated disc haemorrhages bilaterally (Figure 1A). The
maculae, retinal vasculature and retinal peripheries were
otherwise normal in appearance bilaterally.
In terms of initial investigations, visual field testing
showed inferior field loss in the right eye and widespread
field loss in the left eye (Figure 2A). MRI/MRV Head
and Orbits with gadolinium contrast was unremarkable
with no signs of optic nerve pathology, demyelination,
sinus thrombosis, space occupying brain metastasis or
leptomeningeal disease. Routine blood work showed a
normal full blood count, electrolytes, renal function and
liver function. Inflammatory markers were not raised.
After extensive discussion and collaboration between
the oncology, neurology and ophthalmology teams, the
working diagnosis of a bilateral toxic optic neuropathy
was thought to be most likely with docetaxel the likely
causative agent rather than trastuzumab. The patient
was admitted under the oncology team and treated with
high dose steroids: initially dexamethasone 8 milligrams
twice daily orally for 24 hrs, followed by intravenous
pulse methylprednisolone 1 gram once daily for 3 days
on neurology advice.
Over the next 36 hours more extensive investigations
were undertaken. Further blood work including ANA,
dsDNA, Rheumatoid factor, ANCA, ACE, antiphospholi-
pid antibodies, and anti-neuronal antibodies (anti-HU/Ri/
Yo/PCA-2) were all negative. Quantiferon Gold, Toxo-
plasma and syphilis serology and CMV/EBV IgM were
also negative. Serum levels of vitamins potentially causing
a nutritional optic neuropathy were normal as well. Chest
X-ray was unremarkable. Lumbar puncture showed an
opening pressure of 11 cm of H2O and CSF analysis
showed no leucocytes or blood, and protein and glucose
levels within normal limits. Cryptococcal serology and
HSV PCR were negative on the CSF sample. Transtho-
racic echocardiography and carotid ultrasound were both
normal. CT Chest/Abdomen/Pelvis was unremarkable.
Unfortunately ophthalmic electrophysiological testing was
not possible in this patient.
Figure 1 Optic disc photographs. A- Right Optic Disc on Presentation, unfortunately the Left Optic Disc could not be photographed
adequately. B- Right Optic Disc 1 Month later with swelling and hemorrhage resolving. C- Left Optic Disc 1 Month later with swelling resolving.
D- Right Optic Disc 3 Months later. E- Left Optic Disc 3 Months later.
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examination revealed gradual worsening in best-corrected
visual acuity to 6/30 in the right eye and 6/120 in the left
eye, although the patient’s vision was seen to fluctuate
over this period. Serial visual field testing also showed
progression of visual field defects bilaterally despite a
stable optic nerve head appearance on examination
(Figure 2B). On the 4th day of admission, after 3 doses
of methylprednisolone, the patient reported slight im-
proved in central vision bilaterally with best-corrected
visual acuity of 6/9 in the right eye and 6/9 in the left
eye. Visual field testing at this time was stable in both
eyes (Figure 2C). The patient was then discharged from
hospital on 70 mg of oral prednisone daily which was
to be tapered down over 2 months.Subsequent review over the next 3 months showed
stabilisation of visual acuity, resolution of optic nerve
head swelling and haemorrhage (Figure1 B-E) and reso-
lution of visual field defects bilaterally (Figure 2D-E).
Docetaxel chemotherapy was discontinued but the pa-
tient has since completed 8 further cycles of trastuzu-
mab therapy without any complication. Steroids were
successfully ceased with no relapse of symptoms.
After biochemical assessment of the pituitary-gonadal
axis confirmed that the patient was postmenopausal, ad-
juvant endocrine therapy with an aromatase inhibitor –
letrozole (1-letrozole) was safely commenced with no
deterioration in vision. Three months after discharge,
best-corrected visual acuity was 6/9 bilaterally. Trastuzu-
mab therapy is planned to continue for 1 year in total in
Figure 2 Evolution of visual field testing (24-2) over the course of docetaxel toxic optic neuropathy (Total Deviation and Grayscale).
A- On Presentation, B- 5 days after presentation, C- 3 weeks after presentation, D- 5 weeks after presentation, E- 13 weeks after presentation.
Moloney et al. BMC Ophthalmology 2014, 14:18 Page 4 of 6
http://www.biomedcentral.com/1471-2415/14/18addition to 5 years of letrozole therapy as per inter-
national guidelines [14]. The patient was strongly en-
couraged to quit smoking.
Conclusion
Wang and Sadun recently proposed 5 postulates required
for establishing a causal link between a toxic agent and an
optic neuropathy [15]. These include having a strong bio-
logical basis for the optic neuropathy, an association dem-
onstrated on a dose-response curve, long duration of toxin
exposure as a risk factor, recovery on discontinuation of the
toxin and predominant bilaterally of the neuropathy. Wepropose that our patient developed a docetaxel-induced
toxic optic neuropathy due to the strong temporal relation-
ship between docetaxel administration and subsequent
development of bilateral visual loss and visual field defects.
This then correlates with bilateral visual recovery after
docetaxel therapy discontinuation and treatment with
corticosteroids. The extensive investigations our patient
underwent also discount other causes for her optic neur-
opathy. In our case, trastuzumab was continued due to its
indispensable role on the patient’s malignancy related prog-
nosis. To our knowledge, there has only been 1 described
case of trastuzumab induced ocular toxicity and that case
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was discounted as the causative agent because further tras-
tuzumab cycles have not reproduced optic neuropathy.
Because docetaxel has not previously been reported
to cause optic neuropathy, the scientific rationale for
the causative mechanism of this condition is difficult
to explain from a single reported case. However, we
hypothesize that this toxic neuropathy is most likely
caused by an underlying ischemic or neurotoxic insult to
the optic nerve retinal ganglion axons. Although there is
limited literature linking docetaxel to optic nerve dys-
function, the other major taxane, paclitaxel, has been
previously reported to cause optic nerve dysfunction on
both electroretinography and visual-evoked potential
testing [17]. These optic nerve changes were reported
in patients who experienced scintillation scotoma and
photopsias mainly during paclitaxel infusion [18-20].
These symptoms were usually transient but some pa-
tients did have prolonged visual loss. Other studies
have linked this symptomatology to electrophysiological
changes in the retina and optic nerve [10,17,21] with
Scaioli et al. [17] proposing that these changes could
be caused by vascular dysregulation and potentially
vasospasm in retinal and optic nerve vasculature. This
vascular hypothesis could be supported by the clinical
appearance of optic nerve head swelling/haemorrhages
in our patient that was consistent with a non-arteritic
acute ischemic optic neuropathy. Interestingly, this ap-
pearance parallels the optic neuropathy associated with
interferon alpha therapy which is also thought to be
caused by ischemia [22].
In contrast to a potential vascular mechanism, other
authors have hypothesized that taxane-induced optic
nerve dysfunction could also potentially be due to
neurotoxicity of the optic nerve [19]. Gianni et al. [19]
suggest that optic nerve dysfunction could be caused by
a similar mechanism to that which causes the peripheral
neuropathy induced by both docetaxel and paclitaxel.
Although the mechanism of this neurotoxicity has not
yet been fully elucidated, it is known that taxanes pro-
mote the aggregation of intracellular microtubules in
axons leading to dysfunction of axonal transport and
thus leading to distal sensory and motor axonal neur-
opathy. It is well documented that taxanes easily pene-
trate the blood-brain barrier, therefore it seems logical
that this same mechanism could also occur in the cen-
tral nervous system leading to direct axonal injury and
neuropathy [23,24].
Whether the pathogenesis of this condition is due to
optic nerve head ischemia, neurotoxicity or another
mechanism remains to be demonstrated. Whilst it is
conceivable that docetaxel therapy was unrelated to our
patient’s optic neuropathy, we believe it is difficult to
discount our hypothesis due to the temporal relationshipbetween docetaxel infusion and symptom onset, subse-
quent resolution and the lack of other underlying risk
factors, medications or evidence of other cause. Our case
demonstrates that discontinuation of docetaxel therapy
and treatment with corticosteroids to address any associ-
ated optic nerve inflammation is efficacious in halting
the progression of a possible docetaxel-induced optic
neuropathy and can result in visual recovery over several
months. We recommend that all patients who experi-
ence visual disturbance during docetaxel chemotherapy
should be examined by an ophthalmologist so that po-
tentially blinding long term sequelae are avoided.
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